Botulinum Toxin Market is Growing Dynamically at a Promising CAGR of 10.3% During Forecast to 2025
Market Overview:
In this Market
Research Future (MRFR) market note, the global botulinum toxin market is
discussed. The surge in cases of spasticity, cervical dystonia, and chronic
migraine, growing demand for facial aesthetics, and increasing product launches
and approvals by key players are responsible for driving the growth of the global
botulinum toxin market. However, adverse
effects associated with botulinum toxin and poor reimbursement policies are
expected to hamper the market growth. Currently, the market is dominated by several market players.
Botulinum
Toxin Market is expected to register a CAGR of 10.3% during the forecast period, with a market value of USD 9,442.93 Million by 2025.
The growing
competition among existing and new market players to develop better botulinum
toxin products is expected to drive the market growth. Key companies are also involved
in new product launches, collaborations, and mergers to increase their market
share. For instance, in October 2019, Allergan received approval for Botox by
the US Food and Drug Administration (FDA) to treat the lower limb spasticity in
pediatric patients of age group 2 to 17. Additionally, Merz Pharma GmbH & Co.
KGaA announced product approval for Bocouture from European regulatory
authorities for the treatment of upper facial lines.
Company Landscape:
·
Allergan PLC
·
Merz Pharma
GmbH & Co KGaA
·
Galderma S.A
·
Daewoong
Pharmaceutical Co
·
Ipsen Pharma
·
US WorldMeds,
LLC
·
Evolus
·
Hugel
·
Medytox
·
Revance
Therapeutics
Segmentation:
·
The Global Botulinum Toxin Market, by
type, has been segmented into botulinum toxin type A and B. Rising
adoption of botulinum toxin in aesthetic procedures as compared to tissue fillers
and increasing product approvals by regulatory authorities is anticipated to
drive the growth of this segment during the forecast period. As per the Plastic
Surgery Statistics Report published in 2018 by the American Society of Plastic
Surgeons, the number of cosmetic minimally-invasive procedures involving the
use of botulinum toxin type A was 7.43 million in 2018, whereas the processes
involving the use of soft tissue fillers were 2.67 million in 2018 in the US.
·
The Global Botulinum Toxin
Market, by application segment, has been segmented into therapeutic
application and aesthetics applications. The therapeutics segment has been
further divided into a chronic migraine, spasticity, cervical dystonia,
overactive bladder, blepharospasm, and others.
·
Based on end-user, the global botulinum
toxin market has been classified into dermatology centers, hospitals &
clinics, and others.
Asia Pacific botulinum
toxin market is projected to exhibit the highest CAGR during the forecast
period.
Asia-Pacific is the
fastest-growing market with a CAGR of 11.01% for botulinum toxin due to the growing
geriatric population, rising per capita disposable income, developing
healthcare infrastructure, medical tourism, and booming entertainment industry. India, China, and Japan are the major contributors to
the market. Thus, the high cost of aesthetics procedures and lack of awareness
among the people may slow the growth of the market.
Comments
Post a Comment